Assenagon Asset Management S.A. Has $76.50 Million Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Assenagon Asset Management S.A. boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 668.3% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 153,729 shares of the medical research company’s stock after acquiring an additional 133,719 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Thermo Fisher Scientific were worth $76,496,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the business. LaFleur & Godfrey LLC raised its holdings in Thermo Fisher Scientific by 9.1% during the fourth quarter. LaFleur & Godfrey LLC now owns 29,767 shares of the medical research company’s stock valued at $15,486,000 after buying an additional 2,488 shares in the last quarter. Brighton Jones LLC increased its holdings in shares of Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after acquiring an additional 988 shares during the last quarter. Union Bancaire Privee UBP SA acquired a new stake in Thermo Fisher Scientific in the 4th quarter worth approximately $71,877,000. Revolve Wealth Partners LLC boosted its position in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after purchasing an additional 20 shares during the period. Finally, Empowered Funds LLC grew its holdings in Thermo Fisher Scientific by 17.8% during the fourth quarter. Empowered Funds LLC now owns 11,408 shares of the medical research company’s stock valued at $5,935,000 after purchasing an additional 1,720 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Price Performance

NYSE:TMO opened at $415.25 on Thursday. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The firm has a market cap of $156.76 billion, a PE ratio of 25.12, a price-to-earnings-growth ratio of 2.99 and a beta of 0.78. Thermo Fisher Scientific Inc. has a 12 month low of $390.50 and a 12 month high of $627.88. The company’s 50-day moving average price is $417.57 and its two-hundred day moving average price is $493.84.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The firm had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. During the same quarter in the previous year, the company posted $5.11 EPS. The business’s revenue for the quarter was up .2% compared to the same quarter last year. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.41%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific’s dividend payout ratio is 10.09%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the transaction, the executive vice president now owns 23,167 shares of the company’s stock, valued at $9,960,188.31. This represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.33% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on TMO. Citigroup decreased their price objective on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Scotiabank decreased their price target on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a “sector perform” rating for the company in a report on Friday, April 25th. Evercore ISI dropped their price objective on Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating on the stock in a research note on Thursday, April 24th. Stifel Nicolaus decreased their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating for the company in a research note on Thursday, April 24th. Finally, Wells Fargo & Company cut their price target on Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating for the company in a report on Thursday, April 24th. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average target price of $605.30.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.